Indication: Acute Myeloid Leukemia (AML)

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ? 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Untreated IDH1 Mutated AML

Sub-indication: AML with IDH1 mutation

Line of Therapy: treatment naive

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Agios Pharmaceuticals, Inc

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.